imlunestrant

News

Lilly brings second oral SERD to market for breast cancer

Lilly's Inluriyo is the second oral SERD to reach the US market for ESR1-mutated breast cancer, setting up a market tussle with Menarini's Orserdu.

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

News

End of the line for Sanofi's SERD amcenestrant as it fails f...

Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline prospects – after it missed the mark in another clinical trial.

Lilly brings second oral SERD to market for breast cancer

Data cues up AZ oral SERD filing in first-line breast cancer

End of the line for Sanofi's SERD amcenestrant as it fails f...

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks